Overview

Ruxolitinib in Combination With Autotransplant

Status:
Withdrawn

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

Summary

To determine the safety of the approach of giving RUXOLITINIB before and after an autologous stem cell transplant, as measured by graft failure or death.

Phase:

N/A

Details

Lead Sponsor:

Marina Kremyanskaya

Collaborator:

Incyte Corporation

Treatments:

Busulfan
Lenograstim